Literature DB >> 1701342

Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells.

P Nisticò1, R Tecce, P Giacomini, A Cavallari, I D'Agnano, P B Fisher, P G Natali.   

Abstract

Twenty-five early-passage (less than or equal to 8) melanoma cell lines, isolated from ten patients with metastatic melanoma, were analyzed by a combination of serological, immunochemical, and molecular methods for mRNA levels, synthesis, and surface expression of MHC class I and class II antigens prior to and following exposure to recombinant human leukocyte (IFN-alpha A), fibroblast (IFN-beta), and immune (IFN-gamma) interferon. All the cell lines expressed variable levels of HLA class I gene products that were up-regulated to different extents upon exposure to specific interferons (IFNs). HLA class II antigens were expressed in 22 of the 25 melanoma lines and IFN-gamma increased the levels of class II mRNA, protein synthesis, and surface expression in all cultures displaying baseline expression. A significant up-regulation of class II antigen expression by IFN-alpha or -beta, associated with higher levels of class II transcripts and enhanced synthesis, was found only in two early-passage human melanoma cell lines. In three lesions from the same patient which did not constitutively express class II antigens, no expression of these glycoproteins could be induced with any of the IFNs. These results indicate that IFN-gamma does not act as a de novo inducer of class II antigen expression in early-passage human melanoma cell lines. This hypothesis is further supported by analysis of class II-associated invariant chain (Ii) expression, which is expressed and induced by IFNs in a manner similar to that of class II antigens. The present study also indicates that early-passage metastatic melanoma lesions from the same patient are heterogeneous in their de novo expression of major histocompatibility antigens and in their modulation by IFNs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701342

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC).

Authors:  K J Palmer; M Harries; M E Gore; M K Collins
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

2.  Parasite Manipulation of the Invariant Chain and the Peptide Editor H2-DM Affects Major Histocompatibility Complex Class II Antigen Presentation during Toxoplasma gondii Infection.

Authors:  Louis-Philippe Leroux; Manami Nishi; Sandy El-Hage; Barbara A Fox; David J Bzik; Florence S Dzierszinski
Journal:  Infect Immun       Date:  2015-07-20       Impact factor: 3.441

3.  Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.

Authors:  Joyce V Lee; Filomena Housley; Christina Yau; Rachel Nakagawa; Juliane Winkler; Johanna M Anttila; Pauliina M Munne; Mariel Savelius; Kathleen E Houlahan; Daniel Van de Mark; Golzar Hemmati; Grace A Hernandez; Yibing Zhang; Susan Samson; Carole Baas; Laura J Esserman; Laura J van 't Veer; Hope S Rugo; Christina Curtis; Juha Klefström; Mehrdad Matloubian; Andrei Goga
Journal:  Nat Commun       Date:  2022-06-27       Impact factor: 17.694

4.  Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.

Authors:  P Nisticò; R Mortarini; L B De Monte; A Mazzocchi; M Mariani; F Malavasi; G Parmiani; P G Natali; A Anichini
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

5.  Generation and characterization of two human alpha/beta T cell clones. Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway.

Authors:  P Nisticò; P De Berardinis; S Morrone; T Alonzi; C Buono; I Venturo; P G Natali
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

6.  Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma.

Authors:  L G LeMay; J Kan-Mitchell; P Goedegebuure; W Harel; M S Mitchell
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

7.  Effects of interferon alfa and gamma on human uveal melanoma cells in vitro.

Authors:  I de Waard-Siebinga; W M Creyghton; J Kool; M J Jager
Journal:  Br J Ophthalmol       Date:  1995-09       Impact factor: 4.638

8.  Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.

Authors:  Francesco Sabbatino; Yangyang Wang; Giosuè Scognamiglio; Elvira Favoino; Steven A Feldman; Vincenzo Villani; Keith T Flaherty; Sjoerd Nota; Diana Giannarelli; Ester Simeone; Anna M Anniciello; Giuseppe Palmieri; Stefano Pepe; Gerardo Botti; Paolo A Ascierto; Cristina R Ferrone; Soldano Ferrone
Journal:  J Natl Cancer Inst       Date:  2016-02-05       Impact factor: 11.816

9.  Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.

Authors:  M Theobald; J Biggs; J Hernández; J Lustgarten; C Labadie; L A Sherman
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

10.  On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases.

Authors:  M R Bernsen; L Håkansson; B Gustafsson; L Krysander; B Rettrup; D Ruiter; A Håkansson
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.